Community Oncologist: A Key Player in CAR-T Cell Therapy
Community oncologists help refer appropriate patients to authorized treatment centers.
News
Latest News
Rates of Head, Neck Melanoma Up in North American Youth
Risk for head, neck melanoma higher for male sex, older age, non-Hispanic white ethnicity
Differences in Postrelapse Mortality May be Driving Racial/Ethnic Disparities Observed in Children With Hodgkin Lymphoma
Study sought to determine if response to upfront treatment in children and adolescents with Hodgkin lymphoma is influenced by race/ethnicity.
Physician Experience With Rituximab Affected Rate of Early Discontinuation in NHL
Early discontinuation of rituximab in patients with B-cell non-Hodgkin lymphoma was linked with worse survival.
Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenström Macroglobulinemia
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
Single Nucleotide Polymorphisms Associated With ALL in Children With Down Syndrome
Researchers conducted a meta-analysis to evaluate possible associations between certain genetic variants and risk for acute lymphoblastic leukemia.
ASCO Releases Guideline on Addressing Osteoporosis Risk With Nonmetastatic Cancer
The guideline includes strategies to identify patients with nonmetastatic cancer who may be at a higher risk for osteoporotic fractures
Two New Radiomics Features Predict Lung Cancer Survival in LDCT Screening
Screening patients with lung cancer using low-dose computed tomography (LDCT) has been associated with reducing lung cancer mortality as much as 20%, but the technique remains limited.
Low-Dose Computed Tomography Used to Screen First Responders for Lung Cancer
Occupational exposure account for 30% of all lung cancer diagnosis in the United States.
Genomic Assay Shows Utility in Selecting NSCLC Patients for Targeted Therapy
Next-generation sequencing of circulating tumor DNA (ctDNA) may identify patients who are likely to benefit from targeted therapy for NSCLC.
KRAS-Mutant NSCLC Exhibits Different Genetic, Molecular Characteristics Across Racial Groups
Researchers found that molecular profiles of patients with KRAS-mutant NSCLC differ among patients from various racial groups.
EGFR-Positive Lung Cancer Diagnosis and Patient Quality of Life
Cost of therapy was a major concern among a majority (69%) of patients with lung cancer who responded to the survey.
Risk Model Predicts Survival in NSCLC Patients Treated with Immunotherapy
Researchers identified and validated novel risk groups models that predict OS and PFS among NSCLC patients treated with immunotherapy.
Pneumonitis and Survival Outcomes in Patients With NSCLC Treated With Durvalumab
Researchers examined real-life outcomes with the PACIFIC paradigm and found that the higher incidence of pneumonitis did not affect overall survival.
Assessing the Gut Microbiome of Patients With Lung Cancer Receiving Immunotherapy
Researchers also found differences in the composition of the gut microbiome between patients with lung cancer who experienced toxicity and those who did not.
Want to read more?
Please login or register first to view this content.
